Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Lion With Skin Cancer Has Received Radiation Therapy In Hospital May 23, 2019 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 Load more HOT NEWS Los obstáculos en la atención para las personas LGBTQ con cáncer:... EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment...
